CBD Eye-Pressure Effects Changed Direction in a CB1 Knockout Mouse Comparison
An ocular review describes topical CBD increasing eye pressure in ordinary mice but decreasing it in CB1 knockout mice. The opposing responses limit a simple claim that CBD consistently lowers intraocular pressure.
The genotype changed the experimental result
At a reported topical concentration of 5 mM, the reviewed mouse study found increased intraocular pressure at one and four hours. In mice lacking CB1 receptors, CBD decreased pressure at the one-hour observation, with the review attributing that response to GPR18 activation. A concentration in an ocular preparation is not a human oral dose or blood concentration.
The wider literature was mixed
The review identifies nine reports with different directions: four found no pressure effect, three found decreases and two found increases. These reports used different systems and conditions. Counting them does not yield a pooled clinical effect or establish that each contributes equal evidence about patients.
A knockout result does not identify a patient subgroup
Deleting a receptor in an experimental animal is different from observing ordinary variation in people. The study cannot identify which patient would have a pressure reduction, and it does not justify a clinical CBD regimen. Pressure change is also distinct from preserved visual function. The appropriate conclusion retains the genotype, preparation and timing, while recognizing that the review did not establish one uniform direction of CBD’s ocular-pressure effect.
Related analysis: the broader review findings and limitations.
Research cited
This analysis draws on the supplied review. Individual studies are discussed as summarized there: Aebersold, Duff, Sloan and Song (2021). Cannabidiol Signaling in the Eye and Its Potential as an Ocular Therapeutic Agent.
